Background
==========

The challenge of identification and characterization of susceptibility genes for complex multifactorial diseases is partly due to the limitations of parametric statistical methods for detection of gene effects that are dependent solely or partially on interactions with other genes and with environmental exposures \[[@B1],[@B2]\]. These limitations are reduced by non-parametric methods such as the combinatorial partitioning method (CPM) \[[@B3]\], which has been used to study the effect of many marker loci on quantitative phenotypes. The focus of the method is to form subsets of loci or genotypic partitions within which the trait variability is much lower than between the partitions \[[@B3]\]. The loci in such a set of genotypic partitions are then selected as candidates to influence the given trait and are then cross-validated.

A modification of this method is the multifactor dimensionality reduction (MDR) method, which has been used to study the impact of multiple loci on categorical endpoints such as presence or absence of disease or response to treatment. This is accomplished by reducing the dimensionality of the multilocus data where genotypes from multiple loci are pooled into high-risk and low-risk groups, depending on whether they are more common in affected or in unaffected individuals \[[@B4],[@B5]\]. This approach is so far limited to categorical parameters and cannot be applied to quantitative traits. The only possible approach to association mapping would then be to search for patterns of genotypes at different loci. Pattern recognition by machine learning techniques may then be applied to define pattern frequencies or relationships in a data set \[[@B6]\].

In the present study we have used a variation of the combinatorial partitioning method and compared that to a pattern recognition method by the machine learning approach to identify subsets of SNPs that may predict the levels of metabolites in the estradiol metabolic pathway in healthy post-menopausal women. We have chosen this pathway since a positive correlation between estradiol exposure and risk of breast cancer among postmenopausal women has been rather well documented \[[@B7],[@B8]\], and a significant correlation between plasma estrogen levels and subsequent risk of breast cancer development has been repeatedly described \[[@B9]-[@B12]\]. Estrone is synthesized from cholesterol in a cascade of subsequent hydroxylations \[[@B13]\] (Figure [1](#F1){ref-type="fig"}). After ovary seizure at menopause, the peripheral aromatization of androgens, mainly androstenedione into estrone, becomes the main source of circulating estrogen contributing to tumor stimulation \[[@B14]\]. A complex system of enzymes is responsible for estradiol synthesis and its further metabolism: *CYP17, CYP11a, CYP19, 17 β-hydroxysteroid hydrogenase, steroid sulfatase (STS), sulfotransferase (EST), CYP1A1, CYP1B1, Catechol-O-methyltransferase*(\[[@B15]-[@B17]\] (Figure [1](#F1){ref-type="fig"}). Polymorphisms in these enzymes have previously been associated with both breast cancer risk and estradiol levels \[[@B2]\]. In the present report we have studied genetic polymorphism in all these enzymes and addressed the methodological challenge of the analysis of multiple loci 1) by free combinatorial approaches 2) in relation to intergenic haplotype structures within a common biochemical pathway.

Results
=======

The levels of 9 metabolites of the estradiol pathway were studied (Figure [1](#F1){ref-type="fig"}). High correlation was observed between the levels of the different metabolites in the plasma of healthy individuals, metabolites upstream (DHEA, DHEA-S, androstenedione and estrone) as well as downstream (estrone, estradiol, estrone- sulphate) in the pathway (Table [2](#T2){ref-type="table"}). Weight and body mass index significantly correlated with the levels of estrone and estradiol, while levels of DHEA and DHEA-S inversely correlated with age. Testosterone levels correlated with height (Table [3](#T3){ref-type="table"}).

Chi square analysis
-------------------

A total of 18 SNPs in 10 genes were genotyped in 109 individuals resulting in a total of 1962 genotypes. The genotype distribution of the studied polymorphisms was significantly different between the groups of individuals with metabolic activities below and above median when Chi square test was applied. The levels of E~1~and E~2~were significantly associated with two polymorphisms in the 3\'UTR of *CYP19*as well as two non-synonymous substitutions in the *CYP1B1*-R48G and A119S (Table [4](#T4){ref-type="table"}). The El level was also associated to the T461N SNP in *CYP1A1*. Several other non-significant trends were observed.

Combinatorial partitioning analysis (Mutual Information Score (MIS))
--------------------------------------------------------------------

The metabolic groups were further re-defined by using other thresholds than the median, using either one optimal threshold, (partitioning A) or two optimal thresholds (Partitioning B). Several moderately significant SNPs using the optimal thresholds approach were found (all SNPs with p-value \< 0.05, Table [5](#T5){ref-type="table"}). Leave one out cross validation analysis was performed to find sets of genotypes that jointly predict the value of the trait (high or low levels). Estrone levels partitioned into samples with values \< 68.2 pmol/l and \>68.2 pmol/l revealing a maximal difference in genotype distribution. A graphical representation (infogram) of the genotypes for each locus and this partition is shown in Figure [2A](#F2){ref-type="fig"}, where each row corresponds to a SNP and each column -- to a sample. Figure [2B](#F2){ref-type="fig"} shows the stack diagram. The leave one out cross validation method showed that while one SNP can make only \~50% correct predictions of the estrone levels at this partition, combining 6 SNPs, including *CYP1A1m4, CYP1B1*A119S, *CYP1A1m2, CYP19utr3\'*SNPS, *GSTP1, COMT*allows 65% correct prediction (Figure [2C](#F2){ref-type="fig"}). Two of the selected polymorphisms were known to be functional at the metabolic level from previous studies *in vitro*. In the case of random labels, the probability of finding a set of SNPs that can make better prediction was found to be 0.16 based on 100 simulations.

Locus *CYP11A1*was a microsatellite repeat with 10 variant repeat length alleles. All variant alleles were categorized together: A1/A1 (wt/wt), A1/mut, mut/mut. The QT scores and p-values for this locus and each metabolite were calculated and significant differences were found for several of the metabolites. The variant allele was more frequent in women with DHEA-S level\>92.6 μg/dl than in women with DHEA-S levels\<92.6 μg/dl (p \< 0.042). In the two threshold analysis the significance was even higher (p = 0.004) when comparing individuals with DHEA-S levels\<69.7 μg/dl to those with DHEA-S levels\>92.6 μg/dl (Figure [3A](#F3){ref-type="fig"}); stack diagram is shown in Figure [3B](#F3){ref-type="fig"}. For estrone the p-value was 0.008 when comparing groups of women with estrone \>133 pmol/l to those with estrone\< 133 pmol/l. Four women with estrone level \> 133 pmol/l have genotypes A2/A2 and A4/A4. Similar to estrone, levels of estradiol were associated with the *CYP11A*variants when comparing individuals with estradiol \> 33 pmol/l to those with estradiol \< 33 pmol/l (p \< 0.06).

Pattern recognition of SNPs in relation to hormone metabolizing enzymes
-----------------------------------------------------------------------

The optimal threshold of the metabolic levels was found by multiple testing close to the median. Interactions between set of SNPs and physical characteristics like age and weight was identified (Fig [4A,B](#F4){ref-type="fig"}). Carriers of the wt *CYP1A1m1*and wt *GSTT1*with age above 64 years and with a body weight above 75 kg were more often in the lower level group of the metabolite DHEA-SO4 (*CorrMAX*0.54(49/56), P-value \< 0.0001) (Figure [4A](#F4){ref-type="fig"}). An interaction between the levels of this metabolite and age and weight (r = 0.44, p \< 0.002), also seen by the conventional Chi square analysis (Table [2](#T2){ref-type="table"}), was detected by this method. Individuals with weight higher than 75 kg carrying the wt *GSTM1*had significantly higher plasma levels of E~1~S, (*CorrMAX*0.43(43/62), p \< 0.003) (Figure [4B](#F4){ref-type="fig"}).

Another pattern of SNPs was found correlated to the estrone level; the variant allele in the 5\' flanking area of *CYP11*in combination with the wt *GSTT1*was present among 12 individuals with a plasma level of estrone above 68 pmol/l, while none of the individuals with E~1~plasma level below 68 pmol/l carried this combination (*CorrMAX*0.36(53/52) P-value 0.05) (Figure [4C](#F4){ref-type="fig"}). Individuals homozygous for the variant alleles in the *HSD17β*(A3T), *CYP1B1*A119S, and *COMT1*had significantly higher levels of sex hormone binding globulin, (*CorrMAX*0.38(59/49) P-value 0.05) (Figure [4D](#F4){ref-type="fig"}). A colored infogram illustrating the significant differences in SNP patterns above and below the different thresholds is given below each frequency diagram.

Haplotype analysis
------------------

Since some of the SNPs detected by the above methods reside in 3 different genes in vicinity on chromosome 15 we hypothesized that they could form common *intragenic*haplotypes, which in concert might account for a higher activity of the whole pathway. Our findings suggest that the SNPs in *CYP19, CY11*and *CYP1A1*are not inherited at random but form common haplotypes (Figure [5A](#F5){ref-type="fig"}). Individuals with variant number of repeats in the microsatellite repeat of *CYP11*were also carriers of the variant alleles in both loci *CYP1A1mi*and *m2*(D\' 0.350 and 0.194, p \< 0.001 (Bonferroni corrected) and p \< 0.012, respectively) as well as in *CYP19utr3\'*SNP2 (D\' 0.293, p \< 0.001 (Bonferroni corrected) (Figure [5B](#F5){ref-type="fig"}). A schematic presentation of the D\' values is given in Figure [5C](#F5){ref-type="fig"}. High D\' values and significant LD was observed in addition between the 3 SNPs in *CYP19*and the 2 of the 4 SNPs in *CYP1A1*Carriers of the haplotype CTTATATC and CGTA(T)C(T)ATC(A) had more often E~2~levels below median, while carriers of the TGTTT(C)ATC more often had E~2~levels above the median (p \< 0.025) (Figure [5D](#F5){ref-type="fig"}). The SNPs in *CYP1B1*were also in strong linkage disequilibrium forming steady haplotype blocks (Figure [6A,B](#F6){ref-type="fig"}). While the haplotype CGG, containing the C allele in *CYP1B1*R48G and the G alleles in *CYP1B1*A119S and *CYP1B1*V432L was associated with high levels of E~1~and E~2~, the haplotype GTC containing the alternative alleles in locus was associated with lower than median levels (p \< 0.05).

Discussion
==========

Finding effects of groups of SNPs on metabolite levels is complex since the effects of individual SNPs are small and the number of possible SNP combinations is large. We applied two different methods to help identify sets of SNPs correlated to metabolite levels: one using direct two-way classification based on combination of genotypes at selected loci, and another based on leave-one-out-cross-validation analysis. Direct classification method requires sufficiently big sample set for meaningful evaluation of genotype combination frequencies in groups with different metabolite levels. In studies like this with a small number of samples, the LOOCV method allows the evaluation of larger sets of SNPs, since the classifiers are constructed for each locus individually. In the first \"pre-screening\" phase of the genotype-phenotype analysis the metabolic levels were divided by median followed by sets of percentiles of the trait values. Finally, instead of pre-defining cut offs, we let the distribution of the genotypes lead us to those cut offs with a maximal difference in allele distribution. Interestingly, often these best thresholds converged to the median, i.e. for estrone in both the Mutual Information Score method as well as the pattern recognition. Whether or not these resulting cut offs have some physiological significance, remains to be investigated.

Long term exposure to estradiol increases the risk of breast cancer. The mechanisms responsible for this effect have not been firmly established. The prevailing theory proposes that estrogens increase the rate of cell proliferation by stimulating estrogen receptor-mediated transcription and thereby the number of errors occurring during DNA replication \[[@B19],[@B20]\]. An alternative hypothesis proposes that estradiol can be metabolized to quinone derivatives, which can react with DNA and then remove bases from DNA through a process called depurination. Error prone DNA repair then results in point mutations \[[@B21]\]. These two processes, increased cell proliferation and genotoxic metabolite formation, may act in an additive or synergistic fashion to induce cancer. It has been suggested that measuring total E2 concentration and SHBG concentration may be sufficient in large epidemiological studies \[[@B12]\]. Our study shows that even in a small size it is sufficient to monitor only few metabolites as we observed tight correlations between them. Several genetic polymorphisms that may influence estradiol metabolism have been associated with different hormone levels. A polymorphism in *CYP19*, a 3-bp deletion in intron 4 (TTTA)~*n*=\ 7-3~, and a base substitution in exon 3 (G -- \>A) have been reported to be associated with levels of estradiol \[[@B22],[@B23]\]. Genetic polymorphism in the enzymes further hydroxylating estradiol and conjugating its metabolites has also been studied. Women carrying the *COMT*Met/Met genotype had 28% higher 2-hydroxyestrone (*P =*0.08) and 31% higher 16α-hydroxyestrone concentrations (*P=*0.02), compared to women with the Val/Val genotype \[[@B22]\].

The previous studies discussed above analyzed single loci. In a recent breast cancer case -control study, including categorical values only (genotypes), a four-locus susceptibility model including the polymorphisms of *COMT, CYP1A1m1, CYP1B1*codon 48, and *CYP1B1*codon 432 was found associated with breast cancer \[[@B2]\]. The four-locus model was significant at the p = 0.001 level by permutation testing bringing evidence of epistasis, or gene-gene interaction in the case-control setting. Each genotype at a particular locus had an influence on breast cancer disease risk dependent on the genotypes at each of the other three loci. With that in mind, we searched the hormone metabolic pathway for interactions between these loci both at random, combinatorial, without regards to the chromosomal localisation and with regards to the LD in genes that may form common haplotype structures. Two such domains were identified -- the polymorphisms in *CYP1B1*form stable haplotype structures in Norwegian population (Zimarina et al, submitted), and a block on the long arm of chromosome 15 consisting of *CYP11A1*gene close to the *CYP1A1*(less than 1 cM) gene and approximately 27.4 cM telomeric to the *CYP19*gene. Indeed, we found 2 haplotypes in the *CYP1B1*, which were significantly overrepresented in individuals with El and E2 levels above median. Two of the three genotypes (R48G and V432L) were among the best predictors according to the combinatorial partitioning method as well. Furthermore, the same *CYP1B1*haplotypes (CGG and GTC) were associated with breast cancer risk (Zimarina et al, submitted). The CGG haplotype includes both the V432 form of *CYP1B1*and the R48 with higher 4-OH/2-OH E2 metabolic ratio and affinity (Km) towards 17b-estradiol respectively \[[@B24],[@B25]\]. More unexpectedly, we found high D\' values among SNPs residing in different genes but coding for proteins in the same metabolic pathway. The haplotype comprising of the T allele of *CYP19utr3\'*SNP1, the variant number of repeats of *CYP11*and the variant alleles of *CYP1A1m1*and *m2*we associated with high E2 levels (above median). Upregulation of *CYP1A1*by dioxin derivatives through the Ah receptor leads to down-regulation of *CYP19*and *ER*. The close location of these genes gives an attractive opportunity to study whether they are regulated by a common regulatory unit. The haplotype structures may vary from population to population -- hence explain the variability of the published data on various susceptibility alleles in a number of genes.

The fact that we manage to predict correctly 65% of the individuals according to their metabolic levels based on this limited selection of SNPs in healthy individuals, make us believe that we have identified markers of estradiol levels in the present study. Furthermore, we found similar combinations of SNPs as those involved in the susceptibility combinations from the case control study \[[@B2]\]. We are presently conducting a larger study of both cases and controls with a higher SNP density to improve our 65% prediction value. In the last stage of the preparation of this manuscript another large study of 1975 individuals was published \[[@B26]\] confirming our previous initial report of an association of the polymorphism in *CYP193UTR*and aromatase activity \[[@B27]\] and in concordance with our present observation of association with plasma levels. Here we demonstrate that the association can be discovered in much smaller number of individuals (109) using the multilocus data analysis.

Conclusion
==========

These studies provide further evidence that genetic variation may appreciably alter plasma level of sex hormone and thus have an effect on disease risk. We describe an approach for multilocus approach to study multiple low-penetrance genetic factors that together determine quantitative phenotypic traits.

Methods
=======

Blood samples were collected from 109 healthy female volunteers between 55 and 75 years of age on a regular mammographic screening. The women enrolled had 2 consecutive negative mammograms in a period of 2 years and were not on hormone replacement therapy (HRT). The plasma levels of the metabolites E~1~, E~2~, E~1~S, DHEA, androstenedione and testosterone were analysed as described previously in \[[@B28]\]. DNA was isolated from EDTA blood using chloroform/phenol extraction followed by ethanol precipitation according to standard procedures using the Applied Biosystems 340A Nucleic Acid Extractor.

Genotyping
----------

Primer sets and methods for analysis are summarized in Table [1](#T1){ref-type="table"} and as described in \[[@B29],[@B30]\].

Statistical Analysis
--------------------

### Parametric method

Metabolic levels for each metabolite were divided into below and above median and allele and genotype frequency distributions were compared using the Chi square test.

### Non-parametric methods

#### Combinatorial partitioning method

To relax the choice of a metabolite level percentile at which to partition the set of samples, we seek an optimal threshold for each metabolite and each SNP. This optimality is defined by an information theoretic measure of concordance between the partition of the sample set according to genotypes and the partition of the sample set defined by the two sides of a metabolite level threshold. The methods we applied in this dataset are an adaptation of the combinatorial approach of \[[@B3]\] and are briefly described below.

Let (*x*~*i*~*, q*~*i*~), *i*= l,2,\...,*n*denote the measurements for a particular pair consisting of a SNP and a quantitative variable (metabolite level) across all patients. For any such pair we seek a threshold *t*, such that the genotype frequencies in the samples with *q\<t*will be the most different from the genotype frequencies in the samples with *q≥t*. This difference is measured by the mutual information score. The search process itself is exhaustive, considering all possible thresholds. More precisely, for a SNP locus *L*and a quantitative trait *q*, let G be a partition of the sample-set induced by the genotypes at locus *L*. For a threshold *t*, let *C*~*t*~be a binary partition of the sample-set defined by *q\<t*and *q≥t*. The Mutual Information Score (*MIS*) is defined as the difference between the entropy of the partition *C*~*t*~and the entropy of *C*~*t*~conditioned on *G*:

*MIS(C*~*t*~*, G) = H(C*~*t*~*) - H(C*~*t*~/*G*),

where *H*is the entropy or conditional entropy function, as appropriate. The best threshold $\hat{t}$ for a pair (L, *q*) is such that

$MIS(C_{\hat{t}},G)$ = *max*~*min*(*q*)\ ≤*t*≤*max(q)*~*MIS(C*~*t*~*, G).*

The corresponding *p*-values were also calculated, effectively counting all possible ways of partitioning the samples that would give a score better than $MIS(C_{\hat{t}},G)$\[[@B3]\].

In a parallel approach to assessing SNP-metabolite association we tried all possible pairs of thresholds from the set of 5th, 10th, 15th, 20th, 25th etc percentiles of the trait values. For a pair of thresholds a and b, we considered the partition *C*~*a*,*b*~of the samples into samples with trait *q ≤ a*, samples with *a\<q\<b*and samples with *q≥b*. For each such partition, we computed the corresponding mutual information scores *MIS(C*~*a,b*~, *G*) and picked the pair of thresholds ($\hat{a},\hat{b}$) that gave maximum score. The calculated p-values take into account the multiple search over all possible thresholds as described in \[[@B3]\].

Further, for each SNP-trait pair, and a partition of the sample-set *C*defined by a single best threshold or by a pair of best thresholds, we ran leave one out cross validation analysis in order to find a set of SNPs such that genotypes at these SNPs can jointly predict the classification of samples with respect to *C*, i.e. whether the value of the quantitative trait level is above or below threshold \[[@B3]\]. Leave one out cross validation analysis, working with a given subset of SNPs, *S*, consists of the following steps:

1\. Hide a sample

2\. For each SNP in the subset *S*, construct a classifier based on the likelihood of each class of the partition *C*given the genotypes of remaining (non hidden) samples at this locus

3\. Classify the hidden sample using the sum of single-SNP classifiers

4\. Repeat steps 1--3 for each sample, and thus determine the number of correct predictions for the subset *S*

Eventually, we also seek a subset *S*with the best performance. Several search techniques were used for finding best subset of SNPs in order to avoid evaluating each possible subset for each locus/trait pair. These techniques included ordering SNPs by mutual information score and evaluating sets of top scoring SNPs, as well as performing forward and backward sequential searches \[[@B3]\]. Further, we estimated the probability of finding such predictive subsets of SNPs for random labels by simulations.

#### Pattern recognition by the two way classification method

The problem of finding an association between groups of individuals with metabolic levels above or below a certain threshold, referred to as the positive and negative groups, and combinations of genotypes at specific polymorphic loci may be formulated as a two-way classification problem. When evaluating a specific combination of genotypes against a particular patient record, the outcome can be a true-positive (i.e., the individual has all the genotypes in the given combination, and the patient is in the positive group), a true-negative (i.e., the patient does not have the specific combination of genotypes, and the patient is in the negative group), a false-positive (i.e., the individual has all the genotypes the given combination, and the patient is in the negative group) and a false-negative (i.e. the patient does not have the specific combination of genotypes and the patient is in the positive group). For a two-way classification problem, the correlation of a specific combination of genotypes for each combination of SNPs may be computed as

$C = \frac{N_{tp}N_{tn} - N_{fn} + N_{fp}}{\sqrt{\left( {N_{tn} + N_{fn}} \right)\left( {N_{tn} + N_{fp}} \right)\left( {N_{tp} + N_{fn}} \right)\left( {N_{tp} + N_{fp}} \right)}}$

Where *Ntp, Ntn, Nfn*, and *Nfp*, denotes the number of patient records which are respectively true-positive, true-negative, false-negative, and false-positive. The significance of a specific combination of polymorphisms with correlation *CorrMAX*is defined as the probability of finding a better, or just as good, combination of polymorphisms by random. This probability is referred to as the p-value, and is computed by Monte Carlo simulation. The steps for the Monte Carlo procedure are as described in \[[@B31]\]. Briefly, for each individual record, permute the \"above\" or \"below\" labels randomly from the same distribution as in the original data. Calculate *CorrMAX*for the permuted data. If *CorrMAX*for the permuted data is larger than, or equal to *CorrMAX*from the original data, count 1; otherwise count 0. Repeat steps 1, 2 and 3 *k*times. Estimate the p-value, the total count for *CorrMAX*divided by the total number of shuffles *k*. When computing *CorrMAX*for the permuted data, we include all polymorphisms, not only the polymorphisms in the combination to test the significance of. The standard value for *k*(number of repeated steps) is 2000.

### Haplotype analysis

Haplotypes were estimated using PHASE2.0 software. Linkage disequilibrium and D and D\' values were calculated using DNAsp software. Significance of the linkage disequilibrium (LD) was estimated using Fisher exact test with Bonferoni correction for the final p-value.
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![The estradiol metabolic pathway. Estradiol is synthesized from cholesterol in a series of consecutive hydroxylation relations.](1471-2164-7-5-1){#F1}

![(A). Identification of minimal combination of SNPs for maximal prediction value of metabolic expression level of El (estrone) using leave one out cross validation analysis. Estrone levels \<68.2 pmol/l and \>69.2 pmol/l are best predicted by the genotypes in the given order (p \< 0.05). Frequency distribution of the genotypes at each locus: Blue -- common homozygous genotype, green -- heterozygous, yellow -- rare homozygous genotype for each locus (row) and each person (column), white- missing value (A). Columns under heat map labeled by \'\|\' correspond to samples with estrone level \< 68.2 pmol/l, columns labeled by \'-\' correspond to sample with estrone level \> 69.2 pmol/l. Columns are ordered with respect to increasing estrone level (B). Stacked diagrams of frequency distribution of the genotypes at each locus (C).](1471-2164-7-5-2){#F2}

![(A). Identification of minimal combination of SNPs for maximal prediction value of metabolic expression level of DHEA using leave one out cross validation analysis: women with DHEA_SO4 level\>92.6 pmol/l vs women with DHEA_SO4 levels\<92.6 pmol/l (p \< 0.042). Frequency distribution of the genotypes at each locus: Blue -- common homozygous genotype, green -- heterozygous, yellow -- rare homozygous genotype for each locus (row) and each person (column). Columns labeled by \'\|\' correspond to samples with estrone level \< 92.6, columns labeled by \'-\' correspond to sample with estrone level \> 92.6 pmol/l. (B). Stacked diagrams of frequency distribution of the genotypes at each locus.](1471-2164-7-5-3){#F3}

![Pattern recognition: Search for combination of SNPs and physiological parameters associatedwith a given metabolic trait. On top bar diagrams illustrating the distribution of all possible combinations of traits in the metabolic groups below or a bove a given threshold (given in a sqare frame above each bar diagram). (A) **DHEA-SO4 levels***Cyp1a1m1*= mut/mut and *GSTT1*= mut and Age\>64 and Weight\<75, *CorrMAX*0.54(49/56) p \< 0.0001, Age -- Weight, *CorrMAX*0.44 p \< 0.002 Infogram: *CYP1A1m1:*Black = wt/wt Yellow = mut/mut Red = wt/mut; *GSTT1*Black= wt/wt or wt/mut Yellow = mut/mut; Age Yellow = \<64 Black = \>64; Weight Yellow = \>75 Black = \<75 (B). **E1 (Estrone) levels:**The genotype combination *CYP11*= mut and *GSTM1*= wt is present among 12 patients with a level above 68 pmol/l, but non of the patients with a level below 68 pmol/l, *CorrMAX*0.36(53/52) p \< 0.05. (C) **Estrone sulphate**, *GSTM1*-- Weight(75 kg), *CorrMAX*0.43(43/62), p \< 0.003 Infogram1: -*GSTM1*Black = wt/wt or wt/mut Yellow = mut/mut; Weight Yellow = \<75 Black = \>75. (D) **Sex hormone binding globulin**, *HSDA3T*= mut/mut-*CYP1B1A119S*= mut/mut-comt1 = mut/mut. *CorrMAX*0.38(59/49), p \< 0.05 Infogram: *CYP1B1A119S*Red = wt/wt, Yellow = mut/mut, Black = wt/mut, *COMT1:*Red = wt/wt, Yellow = mut/mut, Black = wt/mut.](1471-2164-7-5-4){#F4}

![Linkage disequilibrium between SNPs in 3 genes from the estradiol metabolising pathway situated within 1 cM on chromosome 15: *CYP19*, *CYP11*and *CYP1A*. Samples in each row, variants in columns, high frequency allele -- blue, low frequency allele- yellow **(A)**. LD was observed between the 3 SNPs in the 3\'UTR of *CYP19*and 2 SNPs in *CYP1A1*and the variant allele of *CYP11*with one SNP in CYP19 and another in *CYP1A1*, bold in panel **(B)**. D\', R and Fisher exact test values for all 8 SNPs in this chromosomal area (Site 1--8) are given in panel **(B)**and Fisher exact test results in colour diagram -- blue approximating 0.00**(C)**. Individuals carrying these haplotypes had more often estradiol levels above median **(D)**.](1471-2164-7-5-5){#F5}

![Haploptypes of 3 functional SNPs in CYP1B1, samples in each row, variants in columns, high frequency allele -- blue, low frequency allele- yellow **(A)**, the extent of linkage disequilibrium, D, D\', R and Fisher exact test **(B)**and association to estradiol levels **(C)**. The number of individuals representing each haplotype group with estrone (E1) and estradiol (E2) levels above and below median are given in the table **(C)**.](1471-2164-7-5-6){#F6}

###### 

Summary of the selected SNPs and the respective method of genotyping. Gene/SNP, rs number given when available, aminoacid change or UTR. Primer set: for the assyas developed for this study or otherwise as referred to original publication. Method of analysis: platform and assay selection.

  **Gene/SNP**                    **Primer set**                                                                              **Method of analysis**
  ------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  *CYP11A1, repeat*               f(5\'-6-FAM-GTC-AGC-TGT-ACT-GAA-TTA-CAG-CC-3\') r(5\'-TCT-TGC-CAG-CTT-GGG-CAA-CAT-ACG-3\'   Fragment analysis ABI310, (Applied Biosystems)
  *CYP17, rs 743572*              f 5\'-CAT-TCG-CAC-CTC-TGG-AGT-3\' r 5\'-GGC-TCT-TGG-GGT-ACT-TG-3\'                          RLFP *Msp*A1 (Promega),
  *CYP19 3\'UTRSNP1, rs10046*     5\'-ATA TTC TGG CAA CTG TCT-3\' 5\'-GAG GAT GAC ACT ATT GGC-3\'                             BDT (Big Dye Terminator) sequencing ABI310 (Applied Biosystems)
  *CYP19 3\'UTRSNP2, rs4646*      5\'-GAC AGT GTG TTG AGA GCA TAC AGA-3\' 5\'-TTC TTC ACC GAC TAT TTC TC-3\'                  BDT (Big Dye Terminator) sequencing ABI310 (Applied Biosystems)
  *CYP19 3\'UTRSNP3, rs2255192*   5\'-CAT TGA ATC ATT GTA TGT GGT CAT-3\' 5\'-GGA AAT GGG ATG GAA ATA GAT TAC A-3\'           BDT (Big Dye Terminator) sequencing ABI310 (Applied Biosystems)
  *HSD-A3T, rs3138620*            5\'-6-FAM CAG TAC TAA AGG CCC TAT TAT CAA A-3\' 5\'-AGG CTG CAG TGA GTC CAG AT-3\'          Fragment analysis ABI310, (Applied Biosystems)
  *HSD-DEL, rs8191194*            5\'-6-FAM GTG ACC CAC GAA ACA CAG G-3\' 5\'-CAG AAG GTG AAG AAC TCA TCC A-3\'               Fragment analysis on a ABI310, (Applied Biosystems)
  *CYP1B1 R48G*                   5\'-GCACCCCTGAGTGTCACGCC-3\', 5\'-TTCCAGTGCTCCGAGTAGTG-3\'                                  RFLP, *Rsr II*. (Fermentas)
  *CYP1B1 A119S*                  5\'-GCACCCCTGAGTGTCACGCC-3\', 5\'-TTCCAGTGCTCCGAGTAGTG-3\'                                  RLFP, *NgoM IV*(New England BioLabs)
  *CYP1B1 V432L, rs1056836*       5\'-CCAGCCCAACCTGCCCTATG-3\' 5\'-CCAGGATGGAGATGAAGA-3\'                                     RLFP, *Eco577*(Fermentas)
  *CYP1A1m1 T3801C*               Cascorbi et \[19\].                                                                         See reference
  *CYP1A1m2 I462V, rs1048943*     Cascorbi et \[19\].                                                                         See reference
  *CYP1A1mS T3205C*               Cascorbi et \[19\].                                                                         See reference
  *CYP1A1m4 T461N, rs1799814*     Cascorbi et \[19\].                                                                         See reference
  *COMT, rs4680*                  Matsui et al. 2000, \[20\].                                                                 See reference
  *GSTM1*                         Kristensen et al 1998 \[31\].                                                               See reference
  *GSTT1*                         Kristensen et al 1998\[31\].                                                                See reference
  *GSTP1*                         Kristensen et al 1998\[31\].                                                                See reference

###### 

Correlation between metabolic levels of estradiol and its precursors in the plasma of healthy post-menopausal women. DHEA, dihydroepiandrostenedione, DHEA-SO4, dihydroepiandrostenedione sulfate, androstenedione, testosterone, E1, estrone, E2, estradiol, E1S, estrone- sulphate.

  Metabolite        DHEA               DHEA-SO4            Androstenedione    Testosterone   E1                  E2                  E1S
  ----------------- ------------------ ------------------- ------------------ -------------- ------------------- ------------------- -----
  DHEA              1                                                                                                                
  DNEA-SO4          0.578 p \< 0.001   1                                                                                             
  Androstenedione   0.494 p \< 0.001   0.606 p \< 0.0001   l                                                                         
  Testosterone      NS                 NS                  0.321 p \< 0.001   1                                                      
  E1                0.201 p \< 0.034   0.285 p \< 0.002    0.217 p \< 0.021   NS             1                                       
  E2                NS                 NS                  NS                 NS             0.873 p \< 0.0001   1                   
  E1S               NS                 NS                  NS                 NS             0.776 p \< 0.0001   0.795 p \< 0.0001   1

###### 

Association of estrogen and its precursors with age, height, weight and body mass index.

  Metabolite        Age                 Height              Weight             Body-mass index
  ----------------- ------------------- ------------------- ------------------ ------------------
  DHEA              -0.199 p \< 0.036   NS                  NS                 NS
  DNEA-SO4          -0.218 p \< 0.021   -0.210 p \< 0.026   NS                 NS
  Androstenedione   NS                  NS                  NS                 NS
  Testosterone      NS                  0.300 p \< 0.001    NS                 NS
  E1                NS                  NS                  0.258 p \< 0.006   0.191 p \< 0.042
  E2                NS                  NS                  0.349 p \< 0.000   0.308 p \< 0.001
  E1S               NS                  NS                  NS                 NS

###### 

Statistical significance of distributions of genotypes in the listed estradiol metabolizing enzymes in below and above median levels of metabolites DHEA, dihydroepiandrostenedione, DHEA-SO4, dihydroepiandrostenedione sulfate, androstenedione, testosterone, E1, estrone, E2, estradiol, E1S, estrone- sulphate, SHBG, sex hormone binding globulin. NS -- not significant.

                                                     **Below and above median values**                                                                                     
  --------------------- ---------------------------- ----------------------------------- ------------ ------------ ------------ -------------- -------------- ------------ ----
  ***HSD DEL***         5\'flanking 12 bp deletion   NS                                  NS           NS           NS           NS             NS             NS           NS
  ***HSD A3T***         5\'flanking (AAAT)n          NS                                  NS           NS           p \< 0.053   NS             NS             NS           NS
  ***CYP17***           5\'flanking                  NS                                  NS           NS           NS           NS             NS             NS           NS
  ***CYP19UTRSNP1***    3\'untranslated              NS                                  NS           NS           NS           p \< 0.037     p \< 0.048     NS           NS
  ***CYP19UTRSNP2***    3\'untranslated              NS                                  NS           NS           NS           NS             NS             NS           NS
  ***CYP19 UTRSNP3***   3\'untranslated              NS                                  NS           NS           p \< 0.089   p \< 0.014     p \< 0.013     NS           NS
  ***CYP11***           5\'flanking                  NS                                  P = 0.042    p \< 0.053   NS           p \< 0.003\*   p \< 0.004\*   NS           NS
  ***CYP1B1**R48G*      coding nonsynon R48G         NS                                  p \< 0.082   NS           NS           p \< 0.049     p \< 0.082     p \< 0.042   NS
  ***CYP1B1**A119S*     coding nonsynon A119S        NS                                  NS           NS           NS           p \< 0.073     p \< 0.002     NS           NS
  ***CYP1B1**V432L*     coding nonsynon V432L        NS                                  NS           NS           NS           NS             NS             NS           NS
  ***CYP1A1 m1***       3\'untranslated              NS                                  NS           NS           NS           NS             NS             NS           NS
  ***CYP1A1 m2***       coding nonsynon I462V        NS                                  p \< 0.044   NS           NS           NS             NS             NS           NS
  ***CYP1A1 m3***       3\'untranslated              NS                                  NS           NS           NS           NS             NS             NS           NS
  ***CYP1A1 m4***       coding nonsynon T461N        NS                                  NS           NS           NS           p \< 0.017     NS             NS           NS
  ***COMT***            coding nonsynon V158M        NS                                  NS           p \< 0.02    NS           NS             NS             NS           NS
  ***GSTM1***           gene deletion                NS                                  NS           NS           NS           NS             NS             NS           NS
  ***GSTT1***           gene deletion                NS                                  NS           NS           NS           NS             NS             NS           NS
  ***GSTp1***           coding nonsynon              NS                                  NS           NS           NS           NS             NS             NS           NS

\*ANOVA analysis

###### 

Searching for optimal thresholds approach to identify genotypes associated with quantitative trait (all SNPs with p-value \< 0.05). Partitioning A shows significant results for one optimal threshold (two partitions), and Partitioning B shows the results for two optimal thresholds (three partitions). The calculated p-values take into account the multiple search over all possible thresholds as described in \[3\].

                                     **Partitioning A**   **Partitioning B**
  ----------------- ---------------- -------------------- --------------------
  **Metabolite**    **SNP**          **p-value**          **p-value**
                                                          
  DHEA              *CYP1B1*R48G     NS                   0.022
  E1                *CYP1B1*A119S    0.039                0.0045
  E1S               *CYP1B1*A119S    NS                   0.043
  Androstenedione   *CYP19*UTRSNP1   0.042                NS
  DHEA-SO4          *cyp1A1*m1       NS                   0.010
  DHEA-SO4          *cyp1A1*m2       0.022                0.011
  E1                *cyp1A1*m4       0.042                0.028
